GlassScriptPhysician profile
Anthony Perozich
NPI 1760119937
$1,105.37
in general payments reported to CMS, 2019-2025
15 companies · $567 in 2025
The $567 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $134 · 2024: $404 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $862 · Education: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $862.40 |
| Education | $242.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $243.06 | 2025 | |
| Jazz Pharmaceuticals INC. | $226.34 | 2024 | |
| Optinose US, INC. | $147.21 | 2025 | |
| Medtronic, INC. | $120.33 | 2023 | Intellis Adaptivestim |
| Axsome Therapeutics, INC. | $64.93 | 2024 | Sunosi |
| Sanofi-Aventis U.S. LLC | $52.99 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $48.63 | 2025 | Dupixent |
| Boston Scientific Corporation | $33.47 | 2024 | Ams 700 |
| Inspire Medical Systems, INC. | $32.05 | 2024 | Inspire |
| Avadel Cns Pharmaceuticals, LLC | $29.81 | 2024 | Lumryz |
| Astrazeneca Pharmaceuticals LP | $27.68 | 2025 | Tezspire |
| Aerin Medical INC. | $26.99 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $20.21 | 2025 | Neffy |
| Harmony Biosciences LLC | $17.89 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $13.78 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Perozich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.